enGene (ENGNW) Competitors $0.24 0.00 (-0.04%) As of 05/22/2026 02:42 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ENGNW vs. AIMDW, ALVOW, ARAV, ACABW, and RNAShould you buy enGene stock or one of its competitors? MarketBeat compares enGene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with enGene include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. ENGNW vs. AIMDWENGNW vs. ALVOWENGNW vs. ARAVENGNW vs. ACABWENGNW vs. RNAHow does enGene compare to Ainos?Ainos (NASDAQ:AIMDW) and enGene (NASDAQ:ENGNW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Which has better earnings and valuation, AIMDW or ENGNW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAinos$18.11KN/AN/AN/AN/AenGeneN/AN/AN/AN/AN/A Is AIMDW or ENGNW more profitable? Company Net Margins Return on Equity Return on Assets AinosN/A N/A N/A enGene N/A N/A N/A Does the media refer more to AIMDW or ENGNW? In the previous week, enGene had 6 more articles in the media than Ainos. MarketBeat recorded 7 mentions for enGene and 1 mentions for Ainos. Ainos' average media sentiment score of 0.00 beat enGene's score of -0.04 indicating that Ainos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ainos 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAinos beats enGene on 2 of the 3 factors compared between the two stocks.How does enGene compare to Alvotech?Alvotech (NASDAQ:ALVOW) and enGene (NASDAQ:ENGNW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership. Does the media refer more to ALVOW or ENGNW? In the previous week, enGene had 7 more articles in the media than Alvotech. MarketBeat recorded 7 mentions for enGene and 0 mentions for Alvotech. Alvotech's average media sentiment score of 0.00 beat enGene's score of -0.04 indicating that Alvotech is being referred to more favorably in the media. Company Overall Sentiment Alvotech Neutral enGene Neutral Which has stronger earnings and valuation, ALVOW or ENGNW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$586.32MN/AN/AN/AN/AenGeneN/AN/AN/AN/AN/A Is ALVOW or ENGNW more profitable? Company Net Margins Return on Equity Return on Assets AlvotechN/A N/A N/A enGene N/A N/A N/A SummaryAlvotech beats enGene on 2 of the 3 factors compared between the two stocks.How does enGene compare to Aravive?Aravive (NASDAQ:ARAV) and enGene (NASDAQ:ENGNW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Do institutionals & insiders believe in ARAV or ENGNW? 35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, ARAV or ENGNW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAraviveN/AN/AN/A-$0.90N/AenGeneN/AN/AN/AN/AN/A Is ARAV or ENGNW more profitable? Company Net Margins Return on Equity Return on Assets AraviveN/A N/A N/A enGene N/A N/A N/A Does the media refer more to ARAV or ENGNW? In the previous week, enGene had 7 more articles in the media than Aravive. MarketBeat recorded 7 mentions for enGene and 0 mentions for Aravive. Aravive's average media sentiment score of 0.00 beat enGene's score of -0.04 indicating that Aravive is being referred to more favorably in the media. Company Overall Sentiment Aravive Neutral enGene Neutral SummaryAravive beats enGene on 3 of the 4 factors compared between the two stocks.How does enGene compare to Atlantic Coastal Acquisition Corp. II?enGene (NASDAQ:ENGNW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations. Which has preferable valuation & earnings, ENGNW or ACABW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/AN/AN/AN/AAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A Is ENGNW or ACABW more profitable? Company Net Margins Return on Equity Return on Assets enGeneN/A N/A N/A Atlantic Coastal Acquisition Corp. II N/A N/A N/A Does the media favor ENGNW or ACABW? In the previous week, enGene had 7 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 7 mentions for enGene and 0 mentions for Atlantic Coastal Acquisition Corp. II. Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 beat enGene's score of -0.04 indicating that Atlantic Coastal Acquisition Corp. II is being referred to more favorably in the news media. Company Overall Sentiment enGene Neutral Atlantic Coastal Acquisition Corp. II Neutral SummaryenGene and Atlantic Coastal Acquisition Corp. II tied by winning 1 of the 2 factors compared between the two stocks.How does enGene compare to Avidity Biosciences?Avidity Biosciences (NASDAQ:RNA) and enGene (NASDAQ:ENGNW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Do analysts recommend RNA or ENGNW? Avidity Biosciences presently has a consensus price target of $69.42, suggesting a potential upside of 430.34%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Avidity Biosciences is more favorable than enGene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37enGene 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is RNA or ENGNW more profitable? enGene has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. enGene's return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-3,650.39% -44.92% -39.57% enGene N/A N/A N/A Does the media refer more to RNA or ENGNW? In the previous week, enGene had 6 more articles in the media than Avidity Biosciences. MarketBeat recorded 7 mentions for enGene and 1 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.33 beat enGene's score of -0.04 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, RNA or ENGNW? enGene has lower revenue, but higher earnings than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$36.68M6.10-$322.30MN/AN/AenGeneN/AN/AN/AN/AN/A SummaryAvidity Biosciences beats enGene on 6 of the 10 factors compared between the two stocks. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGNW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENGNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGNW vs. The Competition ExportMetricenGeneBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$464.68M$6.39B$12.31BDividend YieldN/A3.87%2.76%5.31%P/E RatioN/A3.8320.9125.63Price / SalesN/A7,142.84551.1386.36Price / CashN/A13.1344.5756.72Price / BookN/A84.7710.357.12Net IncomeN/A-$96.07M$3.56B$335.28M7 Day Performance11.85%0.54%5.00%2.98%1 Month Performance-90.49%0.66%3.49%2.85%1 Year Performance-68.67%64.43%34.14%35.17% enGene Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNWenGeneN/A$0.240.0%N/AN/A$0.00N/AN/A31AIMDWAinosN/A$0.07+13.2%N/A-57.1%$0.00$18.11KN/A40Positive NewsGap UpALVOWAlvotechN/A$0.24+19.0%N/A-90.5%$0.00$586.32MN/A4Positive NewsARAVAraviveN/A$0.04flatN/AN/A$0.00N/AN/A20High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.00flatN/A-75.0%$0.00N/AN/A15 Related Companies and Tools Related Companies Ainos Alternatives Alvotech Alternatives Aravive Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Avidity Biosciences Alternatives Biofrontera Alternatives Celularity Alternatives Cingulate Alternatives Comera Life Sciences Alternatives Dermata Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGNW) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
